Amid Allergan buyout, AbbVie dumps unwanted Assembly microbiome pact

Assembly Biosciences has been handed back the rights for a series of gastrointestinal microbiome assets from AbbVie as it sweeps out unwanted pacts from its Allergan subsidiary.

The biotech gets back all of its microbiome candidates under the original 2017 deal, worth $50 million upfront, including ABI-M201 and ABI-M301.